Novel aspects on gonadotoxicity and fertility preservation in lymphoproliferative neoplasms.

Erica Silvestris, Gennaro Cormio, Tetiana Skrypets, Miriam Dellino, Angelo Virgilio Paradiso, Attilio Guarini, Carla Minoia

Journal: Critical reviews in oncology/hematology 2020;151():102981

PMID: 32485429

Full Text on Elsevier Science View on PubMed

Abstract

The topic of fertility preservation in patients with a lymphoproliferative disease offers new aspects of debate, due to the introduction of novel chemotherapeutic regimens and small molecules in the clinical landscape. Cancer related infertility is mostly dependent on gonadotoxic treatments and fertile female patients are today addressed to the oocyte cryopreservation or to ovarian cortex fragment cryopreservation. These methods present advantages and disadvantages, which will be discussed in the present review, together with the options for male patients. The recent discovery of functional ovarian stem cells (OCSs) in woman ovarian cortex, opens new avenues offering a innovative procedure for fertility preservation through as model of regenerative medicine. Here, we review the gonadotoxic potential of "classical" chemotherapeutic treatments as well as of "novel" targeted therapies actually employed for lymphoproliferative neoplasms in young patients and revisit both the today available and future chances to preserve and restore fertility after the cancer healing.

Address: Gynecologic Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II" 70124 Bari, Italy. Electronic address: [email protected].; Gynecologic Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II" 70124 Bari, Italy; Department of Biomedical Sciences and Human Oncology, Unit of Obstetrics and Gynecology, University of Bari Aldo Moro, Bari, Italy. Electronic address: [email protected].; Haematology Unit, National Cancer Center, IRCCS Istituto Tumori "Giovanni Paolo II", viale O. Flacco 65, Bari, Italy; Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Italy. Electronic address: [email protected].; Gynecologic Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II" 70124 Bari, Italy. Electronic address: [email protected].; Institutional BioBank, Experimental Oncology and Biobank Management Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy. Electronic address: [email protected].; Haematology Unit, National Cancer Center, IRCCS Istituto Tumori "Giovanni Paolo II", viale O. Flacco 65, Bari, Italy. Electronic address: [email protected].; Haematology Unit, National Cancer Center, IRCCS Istituto Tumori "Giovanni Paolo II", viale O. Flacco 65, Bari, Italy. Electronic address: [email protected].

DOI: 10.1016/j.critrevonc.2020.102981

Link outs

Free resources

Medical:

https://medlineplus.gov/primaryovarianinsufficienc...

Subscription / membership required

Full Text Sources:

MeSH Terms: Antineoplastic Agents, Cryopreservation, Female, Fertility, Fertility Preservation, Humans, Lymphoproliferative Disorders, Male, Neoplasms, Oocytes, Ovary, Primary Ovarian Insufficiency